Harvest Fund Management Co. Ltd Invests $118,000 in Masimo Co. (NASDAQ:MASI)

Harvest Fund Management Co. Ltd purchased a new stake in Masimo Co. (NASDAQ:MASI) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 886 shares of the medical equipment provider’s stock, valued at approximately $118,000.

A number of other large investors have also recently added to or reduced their stakes in the stock. Edgestream Partners L.P. bought a new stake in shares of Masimo in the 2nd quarter worth about $645,000. Simplify Asset Management Inc. increased its holdings in Masimo by 120.4% in the second quarter. Simplify Asset Management Inc. now owns 21,670 shares of the medical equipment provider’s stock valued at $2,729,000 after buying an additional 11,838 shares during the last quarter. ING Groep NV raised its stake in Masimo by 143.3% during the third quarter. ING Groep NV now owns 240,900 shares of the medical equipment provider’s stock valued at $32,119,000 after buying an additional 141,900 shares in the last quarter. Westfield Capital Management Co. LP lifted its holdings in Masimo by 23.2% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock worth $185,869,000 after buying an additional 262,370 shares during the last quarter. Finally, Thrivent Financial for Lutherans grew its position in shares of Masimo by 42.1% in the 2nd quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider’s stock worth $153,314,000 after acquiring an additional 360,497 shares in the last quarter. 85.96% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

MASI has been the topic of several research reports. Piper Sandler upped their price target on Masimo from $165.00 to $180.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. Raymond James raised shares of Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 target price on the stock in a report on Wednesday, November 6th. Stifel Nicolaus reaffirmed a “buy” rating and set a $190.00 price objective (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. BTIG Research increased their price objective on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Finally, Needham & Company LLC restated a “hold” rating on shares of Masimo in a research note on Wednesday, November 6th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Masimo presently has a consensus rating of “Moderate Buy” and an average target price of $167.00.

Masimo Trading Down 0.8 %

Masimo stock opened at $170.89 on Thursday. Masimo Co. has a 52-week low of $91.60 and a 52-week high of $178.27. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $9.15 billion, a price-to-earnings ratio of 117.86 and a beta of 0.97. The firm has a 50-day moving average price of $147.03 and a two-hundred day moving average price of $129.03.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.14. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business had revenue of $504.60 million during the quarter, compared to the consensus estimate of $502.87 million. During the same period in the previous year, the firm posted $0.63 earnings per share. The business’s revenue was up 5.4% on a year-over-year basis. Sell-side analysts expect that Masimo Co. will post 4.04 earnings per share for the current year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.